NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

 
• By Joseph Haas
Graphic Move On Forward Icon Concept
NGM's aldafermin shows strong data in Phase II, moves closer to pivotal study

More from Clinical Trials

More from R&D